Transcription regulators differentiate mesenchymal stem cells into chondroprogenitors, and their
Gene expression
Human umbilical cord
Intervertebral disc degeneration
Mesenchymal stem cells
Regeneration
Transcription factors
Journal
World journal of stem cells
ISSN: 1948-0210
Titre abrégé: World J Stem Cells
Pays: United States
ID NLM: 101535826
Informations de publication
Date de publication:
26 Feb 2022
26 Feb 2022
Historique:
received:
28
02
2021
revised:
02
05
2021
accepted:
06
01
2022
entrez:
18
4
2022
pubmed:
19
4
2022
medline:
19
4
2022
Statut:
ppublish
Résumé
Intervertebral disc degeneration (IVDD) is the leading cause of lower back pain. Disc degeneration is characterized by reduced cellularity and decreased production of extracellular matrix (ECM). Mesenchymal stem cells (MSCs) have been envisioned as a promising treatment for degenerative illnesses. Cell-based therapy using ECM-producing chondrogenic derivatives of MSCs has the potential to restore the functionality of the intervertebral disc (IVD). To investigate the potential of chondrogenic transcription factors to promote differentiation of human umbilical cord MSCs into chondrocytes, and to assess their therapeutic potential in IVD regeneration. MSCs were isolated and characterized morphologically and immunologically by the expression of specific markers. MSCs were then transfected with Isolated cells showed fibroblast-like morphology and expressed CD105, CD90, CD73, CD29, and Vimentin but not CD45 antigens. Overexpression of Genetically modified MSCs accelerate cartilage regeneration, providing a unique opportunity and impetus for stem cell-based therapeutic approach for degenerative disc diseases.
Sections du résumé
BACKGROUND
BACKGROUND
Intervertebral disc degeneration (IVDD) is the leading cause of lower back pain. Disc degeneration is characterized by reduced cellularity and decreased production of extracellular matrix (ECM). Mesenchymal stem cells (MSCs) have been envisioned as a promising treatment for degenerative illnesses. Cell-based therapy using ECM-producing chondrogenic derivatives of MSCs has the potential to restore the functionality of the intervertebral disc (IVD).
AIM
OBJECTIVE
To investigate the potential of chondrogenic transcription factors to promote differentiation of human umbilical cord MSCs into chondrocytes, and to assess their therapeutic potential in IVD regeneration.
METHODS
METHODS
MSCs were isolated and characterized morphologically and immunologically by the expression of specific markers. MSCs were then transfected with
RESULTS
RESULTS
Isolated cells showed fibroblast-like morphology and expressed CD105, CD90, CD73, CD29, and Vimentin but not CD45 antigens. Overexpression of
CONCLUSION
CONCLUSIONS
Genetically modified MSCs accelerate cartilage regeneration, providing a unique opportunity and impetus for stem cell-based therapeutic approach for degenerative disc diseases.
Identifiants
pubmed: 35432734
doi: 10.4252/wjsc.v14.i2.163
pmc: PMC8963382
doi:
Types de publication
Journal Article
Langues
eng
Pagination
163-182Informations de copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: No conflict of interest.
Références
Stem Cells Dev. 2015 Nov 1;24(21):2479-95
pubmed: 26228642
Mater Sci Eng C Mater Biol Appl. 2016 Apr 1;61:437-48
pubmed: 26838870
Int J Mol Med. 2014 Jan;33(1):43-50
pubmed: 24173697
Osteoarthritis Cartilage. 2010 Dec;18(12):1630-8
pubmed: 20950698
Dev Biol. 2003 May 15;257(2):292-301
pubmed: 12729559
Biochem Biophys Res Commun. 2011 Sep 23;413(2):353-7
pubmed: 21903091
J Orthop Res. 2019 Sep;37(9):1946-1955
pubmed: 31042314
Spine (Phila Pa 1976). 2005 Jan 1;30(1):15-24
pubmed: 15626975
Osteoarthritis Cartilage. 2011 Apr;19(4):449-57
pubmed: 21251990
J Bone Joint Surg Am. 1990 Mar;72(3):403-8
pubmed: 2312537
Gene Ther. 2018 Apr;25(2):67-82
pubmed: 29567950
World J Stem Cells. 2019 Jun 26;11(6):347-374
pubmed: 31293717
J Tissue Eng Regen Med. 2018 Jan;12(1):e579-e591
pubmed: 27690334
Arch Oral Biol. 2021 Feb;122:104995
pubmed: 33278647
Neurosurgery. 2019 Jan 1;84(1):272-283
pubmed: 29490072
Science. 1993 May 14;260(5110):926-32
pubmed: 8493530
Mol Cell Biochem. 2020 Jul;470(1-2):99-113
pubmed: 32415417
J Bone Miner Res. 1999 Oct;14(10):1734-41
pubmed: 10491221
J Cell Biochem. 2006 Jan 1;97(1):33-44
pubmed: 16215986
Biotech Histochem. 2002 Mar;77(2):81-3
pubmed: 12083388
Oral Dis. 2009 Sep;15(6):407-13
pubmed: 19371398
Sci Rep. 2020 Aug 25;10(1):14190
pubmed: 32843678
JOR Spine. 2019 Mar 08;2(1):e1045
pubmed: 31463459
Stem Cell Res Ther. 2020 Jan 3;11(1):6
pubmed: 31900222
Eur Cell Mater. 2011 Feb 08;21:122-9
pubmed: 21305475
Stem Cells Dev. 2014 Nov 1;23(21):2553-67
pubmed: 25050446
Dev Dyn. 1997 Aug;209(4):377-86
pubmed: 9264261
Science. 2002 Jun 28;296(5577):2410-3
pubmed: 12089448
Cells. 2012 Nov 16;1(4):1107-20
pubmed: 24710545
Stem Cells Dev. 2011 Oct;20(10):1747-52
pubmed: 21208041
J Orthop Res. 1999 Nov;17(6):829-35
pubmed: 10632449
Methods Mol Biol. 2008;449:153-67
pubmed: 18370090
JOR Spine. 2018 Oct 19;1(4):e1033
pubmed: 31463450
Eur Spine J. 2009 Apr;18(4):439-48
pubmed: 19263091
Hum Gene Ther. 1996 Jun 20;7(10):1261-80
pubmed: 8793551
Osteoarthritis Cartilage. 2019 Jun;27(6):956-964
pubmed: 30721733
Biomater Res. 2017 Oct 23;21:22
pubmed: 29085662
Exp Hematol. 2002 Aug;30(8):870-8
pubmed: 12160838
Biomol Eng. 2007 Feb;24(1):5-21
pubmed: 16963315
Int J Stem Cells. 2017 Nov 30;10(2):184-192
pubmed: 28844128
Arthritis Res Ther. 2007;9(2):R33
pubmed: 17391539
Birth Defects Res C Embryo Today. 2013 Sep;99(3):192-202
pubmed: 24078496
Clin Orthop Relat Res. 1987 Nov;(224):97-104
pubmed: 3665259
Mol Pathol. 2002 Apr;55(2):91-7
pubmed: 11950957
Cell Mol Life Sci. 2016 Sep;73(17):3311-21
pubmed: 27141940
Connect Tissue Res. 1989;23(1):75-88
pubmed: 2632144
Spine (Phila Pa 1976). 1995 Jun 1;20(11):1307-14
pubmed: 7660243
Stem Cells Int. 2012;2012:921053
pubmed: 22550520
Braz J Med Biol Res. 2014 Apr;47(4):279-86
pubmed: 24652327